CA3118996A1 - Polymorphic form of (s,s)-2-n(3-0-(propan-2- ol)-1-propyl- 4-hydroxybenzene)-3- phenylpropylamide and use thereof in the treatment of pain, inflammation and autoimmunity - Google Patents
Polymorphic form of (s,s)-2-n(3-0-(propan-2- ol)-1-propyl- 4-hydroxybenzene)-3- phenylpropylamide and use thereof in the treatment of pain, inflammation and autoimmunity Download PDFInfo
- Publication number
- CA3118996A1 CA3118996A1 CA3118996A CA3118996A CA3118996A1 CA 3118996 A1 CA3118996 A1 CA 3118996A1 CA 3118996 A CA3118996 A CA 3118996A CA 3118996 A CA3118996 A CA 3118996A CA 3118996 A1 CA3118996 A1 CA 3118996A1
- Authority
- CA
- Canada
- Prior art keywords
- polymorph
- pain
- polymorphic form
- inflammation
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19153315.7 | 2019-01-23 | ||
| EP19153315 | 2019-01-23 | ||
| PCT/EP2020/051528 WO2020152226A1 (en) | 2019-01-23 | 2020-01-22 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3118996A1 true CA3118996A1 (en) | 2020-07-30 |
Family
ID=65228356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3118996A Pending CA3118996A1 (en) | 2019-01-23 | 2020-01-22 | Polymorphic form of (s,s)-2-n(3-0-(propan-2- ol)-1-propyl- 4-hydroxybenzene)-3- phenylpropylamide and use thereof in the treatment of pain, inflammation and autoimmunity |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11891350B2 (enExample) |
| EP (1) | EP3860582B1 (enExample) |
| JP (2) | JP7611148B2 (enExample) |
| KR (1) | KR20210119403A (enExample) |
| CN (1) | CN113329746B (enExample) |
| AU (1) | AU2020210831B2 (enExample) |
| BR (1) | BR112021019476A2 (enExample) |
| CA (1) | CA3118996A1 (enExample) |
| DK (1) | DK3860582T3 (enExample) |
| ES (1) | ES2913977T3 (enExample) |
| IL (1) | IL282718B2 (enExample) |
| PL (1) | PL3860582T3 (enExample) |
| PT (1) | PT3860582T (enExample) |
| RS (1) | RS63270B1 (enExample) |
| SG (1) | SG11202111773QA (enExample) |
| WO (1) | WO2020152226A1 (enExample) |
| ZA (1) | ZA202107346B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
| WO2026037478A1 (en) | 2023-08-11 | 2026-02-19 | Novaremed AG | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642290B2 (en) | 2002-10-03 | 2010-01-05 | Novaremed Limited | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| US7674829B2 (en) | 2004-03-26 | 2010-03-09 | Novaremed Limited | Compounds for the treatment of AIDS and other viral diseases |
| GB0804213D0 (en) | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| WO2011030205A1 (en) | 2009-09-09 | 2011-03-17 | Novaremed Ltd. | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation |
| US8802734B2 (en) | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| GB0916073D0 (en) | 2009-09-14 | 2009-10-28 | Cintec Int Ltd | Improvements in and relating to building anchor systems |
| CN103998420B (zh) * | 2011-12-08 | 2018-04-17 | 诺瓦麦有限公司 | (s)2‑n(3‑o‑(丙‑2‑醇)‑1‑丙基‑4‑羟基苯)‑3‑苯基丙酰胺的分离的立体异构形式 |
-
2020
- 2020-01-22 RS RS20220510A patent/RS63270B1/sr unknown
- 2020-01-22 KR KR1020217023524A patent/KR20210119403A/ko not_active Ceased
- 2020-01-22 BR BR112021019476A patent/BR112021019476A2/pt unknown
- 2020-01-22 PT PT207031527T patent/PT3860582T/pt unknown
- 2020-01-22 SG SG11202111773QA patent/SG11202111773QA/en unknown
- 2020-01-22 US US17/295,788 patent/US11891350B2/en active Active
- 2020-01-22 AU AU2020210831A patent/AU2020210831B2/en active Active
- 2020-01-22 CA CA3118996A patent/CA3118996A1/en active Pending
- 2020-01-22 DK DK20703152.7T patent/DK3860582T3/da active
- 2020-01-22 JP JP2021543276A patent/JP7611148B2/ja active Active
- 2020-01-22 ES ES20703152T patent/ES2913977T3/es active Active
- 2020-01-22 EP EP20703152.7A patent/EP3860582B1/en active Active
- 2020-01-22 CN CN202080010393.8A patent/CN113329746B/zh active Active
- 2020-01-22 IL IL282718A patent/IL282718B2/en unknown
- 2020-01-22 PL PL20703152.7T patent/PL3860582T3/pl unknown
- 2020-01-22 WO PCT/EP2020/051528 patent/WO2020152226A1/en not_active Ceased
-
2021
- 2021-09-23 ZA ZA2021/07346A patent/ZA202107346B/en unknown
-
2024
- 2024-12-23 JP JP2024226332A patent/JP2025036479A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3860582T (pt) | 2022-07-08 |
| ES2913977T3 (es) | 2022-06-07 |
| KR20210119403A (ko) | 2021-10-05 |
| SG11202111773QA (en) | 2021-11-29 |
| US20220002228A1 (en) | 2022-01-06 |
| US11891350B2 (en) | 2024-02-06 |
| JP7611148B2 (ja) | 2025-01-09 |
| JP2025036479A (ja) | 2025-03-14 |
| RS63270B1 (sr) | 2022-06-30 |
| EP3860582A1 (en) | 2021-08-11 |
| IL282718A (en) | 2021-06-30 |
| PL3860582T3 (pl) | 2022-08-01 |
| JP2022518288A (ja) | 2022-03-14 |
| ZA202107346B (en) | 2023-10-25 |
| AU2020210831B2 (en) | 2025-02-13 |
| BR112021019476A2 (pt) | 2021-11-30 |
| EP3860582B1 (en) | 2022-05-04 |
| CN113329746A (zh) | 2021-08-31 |
| IL282718B1 (en) | 2024-04-01 |
| WO2020152226A1 (en) | 2020-07-30 |
| IL282718B2 (en) | 2024-08-01 |
| CN113329746B (zh) | 2025-05-02 |
| AU2020210831A1 (en) | 2021-05-20 |
| DK3860582T3 (da) | 2022-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5371790B2 (ja) | 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、５−ｈｔ３および５−ｈｔ１ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジン | |
| JP5603244B2 (ja) | Ｓｅｒｔ、５−ｈｔ３および５−ｈｔ１ａの組み合わせた活性を有する化合物の治療的使用 | |
| JP2025036479A (ja) | 疼痛、炎症および／または自己免疫の処置または予防における使用のための化合物 | |
| JP5657394B2 (ja) | 疼痛の治療又は予防方法 | |
| TWI441630B (zh) | 曲馬朵（Ｔｒａｍａｄｏｌ）和可舒葆（Ｃｏｘｉｂ）之共結晶物 | |
| US20160317479A1 (en) | Method of treating or preventing pain | |
| JP6016179B2 (ja) | 疼痛の治療又は予防用医薬組成物 | |
| HK40061961A (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| HK40061961B (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| CN1107333A (zh) | 那布扶林镇痛剂的长效前体药物及其制备方法 | |
| WO2026037478A1 (en) | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220808 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20240814 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260115 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260115 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260319 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260319 |